Contrasting of LogicBio Therapeutics Inc. (LOGC) and Artelo Biosciences Inc. (NASDAQ:ARTL)

This is therefore a contrasting of the analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation in LogicBio Therapeutics Inc. (NASDAQ:LOGC) and Artelo Biosciences Inc. (NASDAQ:ARTL). The two are both Biotechnology companies that compete with one another.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
LogicBio Therapeutics Inc. 9 0.00 5.40M 0.67 18.57
Artelo Biosciences Inc. 2 0.00 2.42M -1.08 0.00

In table 1 we can see LogicBio Therapeutics Inc. and Artelo Biosciences Inc.’s top-line revenue, earnings per share and valuation.


Table 2 shows LogicBio Therapeutics Inc. and Artelo Biosciences Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
LogicBio Therapeutics Inc. 57,142,857.14% 0% 0%
Artelo Biosciences Inc. 106,716,055.92% 0% 0%

Institutional and Insider Ownership

LogicBio Therapeutics Inc. and Artelo Biosciences Inc. has shares held by institutional investors as follows: 71.2% and 0%. Insiders held roughly 26.97% of LogicBio Therapeutics Inc.’s shares. On the other hand, insiders held about 63.3% of Artelo Biosciences Inc.’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
LogicBio Therapeutics Inc. -1.57% -1.96% -10.07% 42.53% 0% 20.19%
Artelo Biosciences Inc. -2.37% -17.75% 222.55% 229% 0% 186.09%

For the past year LogicBio Therapeutics Inc. was less bullish than Artelo Biosciences Inc.


On 5 of the 8 factors LogicBio Therapeutics Inc. beats Artelo Biosciences Inc.

LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. Its lead product candidate is LB-001 that is been developed for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. LogicBio Therapeutics, Inc. has a partnership with Children's Medical Research Institute (CMRI) of Australia to develop new viral vectors. The company was founded in 2014 and is based in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.